• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

Angiotensin-receptor blockers in diabetic nephropathy [Classics Series]

byAndrew Cheung, MD MBA
August 29, 2013
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Irbesartan was associated with a significantly lower risk of doubling of serum creatinine concentration, developing end-stage renal disease, or death from all causes.

2. Serum creatinine concentration increased at a slower rate in patients receiving irbesartan compared to amlodipine and placebo groups.

Original Date of Publication: September 20, 2001

Study Rundown: The Irbesartan Diabetic Nephropathy Trial assessed the ability of an angiotensin-II-receptor blocker (ARB), irbesartan and a calcium-channel blocker (CCB), amlodipine to protect against renal deterioration in patients with nephropathy due to type 2 diabetes mellitus (T2DM). At the time of this study’s publication, inhibitors of the renin-angiotensin-aldosterone system were known to be effective in patients with nephropathy due to type 1 diabetes but no major trial had investigated these agents in patients with nephropathy due to T2DM. While no significant differences were observed between the amlodipine and placebo treatment groups, irbesartan was associated with a significantly lower relative risk of a composite end point that included doubling of serum creatinine concentration, onset of end-stage renal disease, and death from any cause (P=0.02 for placebo, P=0.006 for amlodipine). Irbesartan was also associated with a slower rate of increase in serum creatinine concentration. These protective effects were found to be independent of the drug’s benefit in lowering blood pressure.

In summary, the ARB, irbesartan has renoprotective effects in addition to lowering blood pressure in patients with nephropathy due to T2DM.

Please click to read study in NEJM

RELATED REPORTS

Empagliflozin use is associated with slower progression of chronic kidney disease

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

DART improves treatment decision-making for patients with chronic kidney disease

In-Depth [randomized, controlled study]: Originally published in 2001 in NEJM, this trial randomly assigned 1,715 patients with a documented diagnosis of T2DM and hypertension to one of three treatment arms: 1) the ARB, irbesartan, 2) the CCB, amlodipine, or 3) placebo. The target blood pressure for all patients was the same (135/85 mmHg or less) and blood pressure was managed as needed with antihypertensive agents other than ACE-inhibitors, ARBs, and CCBs. The primary end point was a composite of doubling of baseline serum creatinine concentration, development of end-stage renal disease, or death from any cause. A composite cardiovascular end point was measured as a secondary outcome.

The relative risk of the primary end point was not significantly different between the placebo and amlodipine groups. Patients receiving irbesartan had a 20% lower relative risk of the primary end point than patients in the placebo group (P=0.02) and a 23% lower risk that those in the amlodipine group (P=0.006). There was no significant difference in the occurrence of the composite cardiovascular outcome among the three groups. Serum creatinine concentration increased at significantly slower rates in the irbesartan group than in the placebo and amlodipine groups. Hyperkalemia requiring discontinuation of trial medication occurred more frequently in the irbesartan group than in the placebo and amlodipine groups.

By Adrienne Cheung and Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: arbchronic kidney diseasetype 2 diabetes
Previous Post

The Val-HeFT trial: Valsartan reduces morbidity in chronic heart failure [Classics Series]

Next Post

Terminology used to describe ductal carcinoma in situ impacts patient preferences

RelatedReports

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
American College of Physicians releases principles to guide patient partnership in health care
Chronic Disease

DART improves treatment decision-making for patients with chronic kidney disease

January 9, 2023
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post
One-year of Herceptin preferable to two-year regimen

Terminology used to describe ductal carcinoma in situ impacts patient preferences

Fluconazole in first trimester not associated with increase in most birth defects

Fluconazole in first trimester not associated with increase in most birth defects

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options